廣告
香港股市 將收市，收市時間：3 小時 2 分鐘

  • 恒指

    18,930.02
    -265.58 (-1.38%)
     

  • 國指

    6,719.13
    -98.55 (-1.45%)
     

  • 上證綜指

    3,126.82
    -31.72 (-1.00%)
     

  • 滬深300

    3,651.79
    -32.66 (-0.89%)
     

  • 美元

    7.8066
    -0.0005 (-0.01%)
     

  • 人民幣

    0.9273
    +0.0004 (+0.04%)
     

  • 道指

    39,671.04
    -201.95 (-0.51%)
     

  • 標普 500

    5,307.01
    -14.40 (-0.27%)
     

  • 納指

    16,801.54
    -31.08 (-0.18%)
     

  • 日圓

    0.0496
    0.0000 (0.00%)
     

  • 歐元

    8.4508
    +0.0024 (+0.03%)
     

  • 英鎊

    9.9320
    +0.0040 (+0.04%)
     

  • 紐約期油

    77.04
    -0.53 (-0.68%)
     

  • 金價

    2,374.80
    -18.10 (-0.76%)
     

  • Bitcoin

    69,426.30
    -184.09 (-0.26%)
     

  • CMC Crypto 200

    1,514.00
    -12.41 (-0.81%)
     

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2 分鐘文章

Aquestive Therapeutics (AQST) reported $12.05 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 8.3%. EPS of -$0.17 for the same period compares to $0.11 a year ago.

The reported revenue represents a surprise of -1.37% over the Zacks Consensus Estimate of $12.22 million. With the consensus EPS estimate being -$0.09, the EPS surprise was -88.89%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

廣告

Here is how Aquestive Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Manufacture and supply revenue: $10.52 million versus the four-analyst average estimate of $10.64 million. The reported number represents a year-over-year change of +7.7%.

  • Revenues- License and royalty revenue: $1.13 million versus $1.20 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +23.2% change.

  • Revenues- Co-development and research fees: $0.40 million compared to the $0.40 million average estimate based on three analysts. The reported number represents a change of -11% year over year.

View all Key Company Metrics for Aquestive Therapeutics here>>>

Shares of Aquestive Therapeutics have returned -14% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Aquestive Therapeutics, Inc. (AQST) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research